PMS53 UTILISATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN QUEBEC, CANADA: IS THERE A CHANGE IN THE PATIENT RISK PROFILE AFTER THE WITHDRAWAL OF ROFECOXIB?
Rahme E 1 , Roussy JP 2 , Lafrance JP 3 , Nedjar H 1 , Morin S 4 1 McGill University Health Centre, Montréal, QC, Canada, 2 Pfizer Canada, Kirkland, QC, Canada, 3 Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, 4 Hôpital Général de Montréal, Montréal, QC, Canada OBJECTIVES: Traditional nonsteroidal anti-inflammatory drug (tNSAID) utilisation has recently increased considerably in the elderly in spite of their higher gastrointestinal (GI) toxicity and an increasing body of evidence pointing to similar cardiovascular (CV) safety compared to celecoxib. The objective is to describe the profile of patients who used celecoxib and tNSAIDs between April 1, 2005 and March 31, 2007 (post-rofecoxib withdrawal period) versus April 1, 2002 and March 31, 2004 in Quebec, Canada. METHODS: Data were obtained from the physician and medication claims databases of the Quebec Health Insurance Agency. All patients 50 years of age and older who used celecoxib or tNSAIDs during the study periods were included. Patients were categorized by GI, CV, congestive heart failure (CHF) and renal risk factors and four risk categories were considered (low, moderate, high, and very high) in each condition. RESULTS: The numbers of patients on celecoxib were 145,596 and 178,714 in the post-vs. pre-period, while those on tNSAIDs were 249,433 and 120,809, respectively. Logistic regression models revealed that users of celecoxib vs. tNSAIDs were more likely to have higher GI risk levels in both periods [post-period (vs. low risk): very high 1.79 (95%CI: 1.63, 1.97), high 1.76 (1.71, 1.81) and moderate 1.30 (1.27, 1.33)]. While users of celecoxib had higher CV risk levels in the pre-period compared to tNSAIDs, their very high CV risk level in the post-period was lower [post-period (vs. low risk): very high 0.85 (0.81, 0.89), high 1.13 (1.10, 1.16) and moderate 1.15 (1.12, 1.17)]. In both periods, the impact of CHF and renal risks on the choice of celecoxib vs. tNSAIDs appears to be less important. CONCLUSIONS: Currently, patients at very high CV risk seem to be less likely to receive celecoxib vs. tNSAIDs, while those with GI risk factors seem more likely to receive celecoxib. Asians, and 2,554 Native Americans who were eligible for total knee replacement surgery based on their ICD 9 codes. Multivariable logistic regressions were used to estimate the racial and ethnic disparities in the rates of actually receiving knee replacement surgery among these eligible subjects. Blinder-Oaxaca decomposition techniques were employed to determine the extent to which racial and ethnic disparities reflect differences in observable population characteristics versus unobserved heterogeneity across racial and ethnic groups. RESULTS: Approximately 90% of Caucasians, 70% of African-Americans, 75% of Latinos and Asians, and 83% of Native Americans who were eligible to receive total knee replacement surgery actually did receive it. These disparities persisted in the multivariable analyses. Compared to Caucasians, the odds of having the total knee surgery was 0.46 for African Americans (p < 0.0001), 0.49 for Latinos (p < 0.0001), 0.45 for Asians (p < 0.0001), and 0.67 for Native Americans (p < 0.0001). The Blinder-Oaxaca decomposition showed that 39%-59% of the observed differences in the racial and ethnic disparities in receiving the total knee replacement surgery can be explained by observed population characteristics, most important of which are differences in age and health insurance coverage by race and ethnicity. CONCLUSIONS: Substantive racial and ethnic disparities exist in total knee replacement surgery among the eligibles. Observable population characteristics account for most of the differences, with age and health insurance key factors driving racial and ethnic disparities in receiving this surgery. Unobserved heterogeneity, which may include physician-patient relationships, mistrust, and cultural factors, are also related to these disparities. Latinos, 3,805 Asians, and 923 Native Americans who were eligible for the total hip replacement surgery. Multivariable logistic regressions were used to estimate the racial and ethnic disparities of actually receiving the replacement surgery among eligible patients. The Blinder-Oaxaca decomposition techniques were employed to determine the extent to which disparities reflect differences in observable population characteristics versus unobserved heterogeneity across racial and ethnic groups. RESULTS: Approximately 77% of Caucasians, 51% of African Americans, 46% of Latinos, 51% of Asians, and 56% of Native Americans who were eligible to receive total hip replacement surgery actually received it. These disparities persisted in the multivariable regressions. Compared to Caucasians, the odds of having total hip replacement surgery was 0.52 for African Americans (p < 0.0001), 0.41 for Latinos (p < 0.0001), 0.44 for Asians (p < 0.0001), and 0.47 for Native Americans (p < 0.0001). The Blinder-Oaxaca decomposition method revealed that 43%-53% of the observed differences between Caucasians vs. African Americans, Latinos, and Asians in receiving total hip replacement surgery can be explained by observed population characteristics, among which differences in age, health insurance coverage, and gender are the major factors associated with these disparities. In contrast, observed population characteristics only explained 3% of the differences between Caucasians vs. Native Americans. CONCLU-SIONS: Substantive racial and ethnic disparities exist in total hip replacement surgery. Observable population characteristics account for most of these differences (with the exception of Native Americans), with age and health insurance being key factors. Unobserved heterogeneity such as unobserved physician-patient relationships, mistrust, and cultural factors, is also related to the disparities, especially for the disparities between Caucasians and Native Americans.
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